Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities

Ahirwar, Kailash; Kumar, Ankit; Srivastava, Nidhi; Saraf, Shubhini A.; Shukla, Rahul

doi:10.1016/j.ijbiomac.2024.131048

International Journal of Biological Macromolecules

2024

DOI: 10.1016/j.ijbiomac.2024.131048

|View full text |Cite

Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities

Kailash Ahirwar,

Ankit Kumar,

Nidhi Srivastava

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the recent progress in therapeutic approaches, the outlook for individuals with glioma remains discouraging. The median survival time for grade 2 and 3 gliomas is approximately 11.6 years and 3 years respectively, the survival duration for individuals diagnosed with grade 4 gliomas is typically restricted to a mere 15 months [3][4][5]. Therefore, gaining an enhanced comprehension of the underlying mechanisms governing glioma occurrence and it is crucial to discover new diagnostic indicators and therapeutic strategies.…”

mentioning

confidence: 99%

NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells

Zhang,

Yu,

et al. 2024

neo

View full text Add to dashboard Cite

The most common primary malignant tumor in the adult brain is glioblastoma multiforme (GBM); however, its underlying pathogenic mechanism remains elusive. The never in mitosis (NIMA)related kinase 2 (NEK2) has been closely associated with the prognosis of various malignancies.Nevertheless, the complete elucidation of NEK2's potential clinical value, particularly in glioma prognosis and development, remains lacking. U87MG and A172 glioblastoma cells were infected with sh-NEK2 lentivirus or oe-NEK2 plasmid to investigate the effect of NEK2 on cell proliferation, migration, and invasion. Cell viability was measured using CCK-8 and colony formation assays, while Transwell assay was utilized to assess cell migration and invasion. Protein expression levels were determined through western blot analysis. Additionally, CGGA and TCGA databases were used for bioinformatics analysis in order to examine the NEK2 expression. Through comprehensive bioinformatics analysis, we identified elevated mRNA expression levels of NEK2 in gliomas compared to normal tissues, which correlated with poor prognosis among glioma patients.Moreover, functional experiments revealed that silencing NEK2 suppressed glioma cell proliferation while overexpression of NEK2 promoted migration and invasion capabilities. Finally, our study uncovered that NEK2 regulates the malignant progression of TP53 wild-type glioblastoma by facilitating TP53 ubiquitination.

show abstract

mentioning

confidence: 99%

NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells

Zhang,

Yu,

et al. 2024

neo

View full text Add to dashboard Cite

show abstract

The nanocarrier strategy for crossing the blood-brain barrier in glioma therapy

Wu,

Wang,

Ren

et al. 2024

Chinese Chemical Letters

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities

Cited by 2 publications

References 218 publications

NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells

NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells

The nanocarrier strategy for crossing the blood-brain barrier in glioma therapy

Contact Info

Product

Resources

About